Zai Lab defers prior profit goal to fund pipeline after Q2 loss, plans trials, first U.S. filing
Zai Lab defers prior profitability goal to fund global pipeline after Q2 loss, plans 3 ZL-1310 trials and first U.S. filing
- Q2 2026 revenue was $106.3 million with net loss of $50.8 million.
- Company plans three registrational trials for DLL3 ADC ZL-1310 by year-end, highlighting the program on the Q2 2026 earnings call.
- First U.S. regulatory submission for ZL-1310 is targeted for next year, according to the Q2 2026 earnings call.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.